Press Release

<<  Back
Printer Friendly Version   View printer-friendly version
BioTime to Present at Two Upcoming Investor Conferences
May 20, 2016

ALAMEDA, Calif.--(BUSINESS WIRE)--May 20, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX) announced that Co-Chief Executive Officer Michael D. West, Ph.D., will present at the 2016 Oppenheimer 17th Annual Israel Conference to be held at the David Intercontinental Hotel in Tel-Aviv on Sunday, May 22, 2016.

Dr. West will also present at the Mauldin Economics 2016 Strategic Investment Conference, in Dallas, Texas on May 25, 2016. The conference features innovative companies with its theme titled “Decade of Disruption.”

Michael West, Ph.D., will be sharing his knowledge as an industry leader and authority in pluripotent stem cells and regenerative medicine, with a particular focus on BioTime’s strategy to lead in the application of the technology in the large and growing markets in age-related degenerative disease. Dr. West will also be participating in two panel discussions to discuss his views on future trends in business and technology.

Panel discussion times will be:
Wednesday, May 25th - 3:20pm - 4:10pm
Thursday, May 26th - 3:55pm - 4:45pm

More information is available at and the presentations will be made available on the BioTime website in the Investor’s section under Events & Presentations.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world’s premier collection of pluripotent cell assets. The foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.


Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime'sSecurities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list:


Source: BioTime, Inc.

BioTime, Inc.
Dan L. Lawrence, 510-775-0510
Investor Contact:
EVC Group, Inc.
Michael Polyviou, 646-445-4800
Media Contact:
Gotham Communications, LLC
Bill Douglass, 646-504-0890